Company news

Entropy Neurodynamics Limited news in 2024

Entropy Neurodynamics Limited's news releases, calls and decks from 2024, newest first.

View company

Positive interim results in Phase 2a TRP-8802 IBS trial

December 17, 2024

Phase 1b extension results meet study objectives

December 15, 2024

Phase 1b determines optimal parameters for TRP-8803 use

November 18, 2024

$6m funding to fast track TRP-8803 clinical trial strategy

October 29, 2024

Pause in Trading

October 27, 2024

TRP-8803 doses deemed safe by SRC following phase 1b study

October 17, 2024

Preliminary Final Report Reporting Adjustments

September 30, 2024

Appendix 4E Preliminary Final Report

August 29, 2024

Completion of patient dosing in maiden TRP-8803 trial

August 25, 2024

Positive Phase 2a fibromyalgia results across all patients

August 11, 2024

Maiden dosing of TRP-8803 completed in global first

July 1, 2024

Reinstatement to Quotation

May 28, 2024

Results of 2024 General Meeting

April 11, 2024

Disclosure Document - Replacement Prospectus

March 28, 2024

Disclosure Document - Prospectus

March 14, 2024

2024 General Meeting Letter of Access, Notice and Proxy

March 12, 2024

EX1 signs binding agreement to acquire Tryp Therapeutics

March 8, 2024

Appendix 4D and Half Year Report for period 31 December 2023

February 26, 2024

Decks in 2024